CMEABIM MOC

Understanding and Managing a Complex Dual Dilemma: Diabetes and Dyslipidemia

Understanding and Managing a Complex Dual Dilemma: Diabetes and Dyslipidemia

This activity is supported by an educational grant from Amgen.

Overview

Author(s)/Faculty: James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA; Harold E. Bays, MD, FTOS, FACC, FACE, FNLA; Sergio Fazio, MD, PhD; George Grunberger, MD, FACP, FACE
Source: Healio Education Lab - Endocrinology
Type: MonographArticles/Items: 6
Release Date: 10/20/2017Expiration Date: 10/19/2018
Credit Type: CME / ABIM MOCNumber of Credits: 1.25
Cost: FreeProvider: Vindico Medical Education
Patients with type 2 diabetes have increased cardiovascular risk. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as effective lipid-lowering compounds, yet their impact on glycemic parameters in patients with diabetes remains unclear. This CME activity will focus on the management of dyslipidemia in patients with diabetes and the role of PCSK9 inhibitors. Expert faculty will review the genetic and clinical trial evidence on PCSK9 inhibition in diabetes, the recommendations for the management of dyslipidemia in patients with diabetes, and the latest safety and efficacy data on the use of PCSK9 inhibitors in patients with diabetes. Case studies will demonstrate how to integrate this information into clinical practice.

CME Information

page 1 of 9